Get the Stockscreener App
7.32
1.53%
0.11
After Hours:
7.27
-0.05
-0.68%
Aurinia Pharmaceuticals Inc stock is traded at $7.32, with a volume of 953.20K.
It is up +1.53% in the last 24 hours and up +2.81% over the past month.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.
See More
Previous Close:
$7.21
Open:
$7.17
24h Volume:
953.20K
Relative Volume:
0.81
Market Cap:
$1.03B
Revenue:
$175.51M
Net Income/Loss:
$-78.02M
P/E Ratio:
-13.81
EPS:
-0.53
Net Cash Flow:
$-34.18M
1W Performance:
-2.27%
1M Performance:
+2.81%
6M Performance:
+43.53%
1Y Performance:
-11.06%
1-Day Range:
$7.09
$7.35
1-Week Range:
$7.03
$7.485
52-Week Range:
$4.71
$10.05
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Name
Aurinia Pharmaceuticals Inc
Sector
Industry
Phone
250-744-2487
Address
#140, 14315 - 118 AVENUE, EDMONTON, BC
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| May-05-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-28-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-25-21 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| May-05-20 | Initiated | Cowen | Outperform |
| Jan-10-20 | Initiated | Jefferies | Buy |
| Dec-16-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-16-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Feb-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-30-17 | Reiterated | H.C. Wainwright | Buy |
| May-18-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-11-17 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-22-17 | Reiterated | FBR & Co. | Outperform |
| Dec-30-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-17-16 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-16 | Initiated | H.C. Wainwright | Buy |
| May-08-15 | Initiated | MLV & Co | Buy |
View All
Aurinia Pharmaceuticals Inc Stock (AUPH) Latest News
Shareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) are in the red if they invested three years ago - Yahoo Finance
Aurinia Pharmaceuticals (AUPH) to Release Earnings on Thursday - MarketBeat
Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024 - The Bakersfield Californian
Axonis Therapeutics Announces $115 Million Series A Financing - Quantisnow
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) surges 5.9%; individual investors who own 51% shares profited along with institutions - Simply Wall St
Objective long/short (AUPH) Report - Stock Traders Daily
Oppenheimer Downgrades Aurinia Pharmaceuticals Inc (AUPH) to a Perform from an Outperform - Knox Daily
Adversity is less terrifying than hope: Aurinia Pharmaceuticals Inc (AUPH) - SETE News
AQR Capital Management LLC Takes Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
AQR Capital Management LLC Buys Shares of 202,241 Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
Aurinia Pharmaceuticals spotlights lupus nephritis drug - Investing.com India
Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024 - BioSpace
Charting the Course: Aurinia Pharmaceuticals Inc’s AUPH Stock Prospects - The InvestChronicle
Aurinia Pharmaceuticals Showcases LUPKYNIS’s Impact at ASN 2024 - TipRanks
Aurinia Pharmaceuticals spotlights lupus nephritis drug By Investing.com - Investing.com UK
Aurinia Pharmaceuticals Inc (AUPH) presents a great opportunity, but the stock is slightly undervalued - US Post News
Market Recap: Aurinia Pharmaceuticals Inc (AUPH)’s Negative Momentum, Closing at 6.84 - The Dwinnex
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Bought by SG Americas Securities LLC - MarketBeat
When the Price of (AUPH) Talks, People Listen - Stock Traders Daily
Algert Global LLC Buys 100,104 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class ActionAUPH - AsiaOne
Corporate and Individual Donations Provide Much-Needed Support to Kidney Patients Impacted by Hurricane Helene Through the American Kidney Fund’s Disaster Relief Program - GlobeNewswire Inc.
Aurinia Pharmaceuticals (NASDAQ:AUPH) shareholders are up 5.0% this past week, but still in the red over the last three years - Simply Wall St
Stonepine Capital Management LLC Takes Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
Short Interest in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Declines By 13.0% - Defense World
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Sees Large Decline in Short Interest - MarketBeat
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Could Be Less Than A Year Away From Profitability - Yahoo Finance
Armistice Capital LLC Sells 1,124,000 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
Japan approves Aurinia's lupus nephritis treatment By Investing.com - Investing.com Australia
Japan approves Aurinia's lupus nephritis treatment - Investing.com India
Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis - BioSpace
Aurinia’s Lupus Drug LUPKYNIS Wins Approval in Japan - TipRanks
Aurinia Pharma Gets Approval in Japan for Lupus Treatment - MarketWatch
Unum Group stock rises Thursday, still underperforms market - MarketWatch
Health Care Lags Market on Cyclical BiasHealth Care Roundup - MarketWatch
Waterloo Capital L.P. Decreases Stake in Ulta Beauty, Inc. (NASDAQ:ULTA) - Defense World
Universal Health Up 23% in 3 Months: Time to Buy or Miss the Boat? - Zacks Investment Research
3 Small Biotech Stocks With The 'Big Mo' Right Now - Seeking Alpha
Leuthold Group LLC Invests $2.76 Million in Urban Outfitters, Inc. (NASDAQ:URBN) - Defense World
Urban Outfitters Q2 2025 Scare Led To A More Fairly Priced Stock. Still A Hold But More Interesting - Seeking Alpha
Aurinia Pharmaceuticals: LUPKYNIS Leading The Way In Lupus Nephritis Treatment - Seeking Alpha
Oppenheimer Asset Management Inc. Grows Stock Position in Ulta Beauty, Inc. (NASDAQ:ULTA) - Defense World
Unitedhealth Group Inc [UNH] gain 10.29% so far this year. What now? - The DBT News
Unum Stock: Core Business Strength Comes Into Greater Focus (UNM) - Seeking Alpha
Allurion Technologies Inc. (NYSE:ALUR) Short Interest Up 8.6% in August - Defense World
UnitedHealth Group Incorporated (UNH): Hedge Funds Are Bullish On This Counter Cyclical and Defensive Stock to Invest In - Yahoo Finance
Alliance Global Partners’s latest rating for UMH stock - Knox Daily
Universal Music shares retain buy rating, price target steady on growth targets - Investing.com
Urban Outfitters (NASDAQ:URBN) Trading Up 4.1% - Defense World
Cantor Fitzgerald upgrades Universal Health Services, Inc. (UHS) stock to a Neutral - Knox Daily
UroGen Pharma reiterates stock target, outperform on strong FDA prospects - Investing.com
Aurinia Pharmaceuticals Inc Stock (AUPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aurinia Pharmaceuticals Inc Stock (AUPH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Balakrishnan Brinda | Director |
May 21 '24 |
Sale |
5.74 |
520 |
2,985 |
17,523 |
| Billen Daniel | Director |
May 21 '24 |
Sale |
5.74 |
5,252 |
30,146 |
28,141 |
| Jayne David R.W. | Director |
May 21 '24 |
Sale |
5.74 |
4,946 |
28,390 |
44,364 |
| Leversage Jill | Director |
May 21 '24 |
Sale |
5.74 |
5,610 |
32,201 |
12,918 |
| MacKay-Dunn R. Hector | Director |
May 21 '24 |
Sale |
5.74 |
5,630 |
32,316 |
18,595 |
| Greenleaf Peter | Chief Executive Officer |
Mar 06 '24 |
Sale |
5.60 |
126,981 |
711,094 |
1,522,114 |
| Miller Joseph M | Chief Financial Officer |
Mar 06 '24 |
Sale |
5.60 |
34,811 |
194,942 |
495,928 |
| Donley Matthew Maxwell | EVP, Ops & Strategy |
Mar 06 '24 |
Sale |
5.51 |
40,665 |
224,064 |
584,072 |
| Habig Scott Michael | Chief Commercial Officer |
Mar 06 '24 |
Sale |
5.60 |
17,777 |
99,551 |
474,587 |
| Robertson Stephen P. | EVP, General Counsel |
Mar 06 '24 |
Sale |
5.60 |
57,745 |
323,372 |
443,824 |
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):